Evidence map›Paper›PMID 34811581›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2022

Sexual dimorphism in cardiac remodeling: the molecular mechanisms ruled by sex hormones in the heart.

Cláudia Ferreira, Fábio Trindade, Rita Ferreira, João Sérgio Neves, Adelino Leite-Moreira, Francisco Amado, Mário Santos, Rita Nogueira-Ferreira

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Cláudia FerreiraLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
Fábio TrindadeDepartment of Surgery and Physiology, Cardiovascular R&D Center (UnIC), Faculty of Medicine, University of Porto, Porto, Portugal.
Rita FerreiraLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
João Sérgio NevesDepartment of Surgery and Physiology, Cardiovascular R&D Center (UnIC), Faculty of Medicine, University of Porto, Porto, Portugal.
Adelino Leite-MoreiraDepartment of Surgery and Physiology, Cardiovascular R&D Center (UnIC), Faculty of Medicine, University of Porto, Porto, Portugal.
Francisco AmadoLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
Mário SantosDepartment of Cardiology, Hospital Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Rita Nogueira-FerreiraDepartment of Surgery and Physiology, Cardiovascular R&D Center (UnIC), Faculty of Medicine, University of Porto, Porto, Portugal. rmferreira@med.up.pt.ORCID http://orcid.org/0000-0001-7059-8237
Universidade do Porto · PTRede de Química e Tecnologia · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is growing in prevalence, due to an increase in aging and comorbidities. Heart failure with reduced ejection fraction (HFrEF) is more common in men, whereas heart failure with preserved ejection fraction (HFpEF) has a higher prevalence in women. However, the reasons for these epidemiological trends are not clear yet. Since HFpEF affects mostly postmenopausal women, sex hormones should play a pivotal role in HFpEF development. Furthermore, for HFpEF, contrary to HFrEF, effective therapeutic approaches are missing. Interestingly, studies evidenced that some therapies can have better results in women than in HFpEF men, emphasizing the necessity of understanding these observations at a molecular level. Thus, herein, we review the molecular mechanisms of estrogen and androgen actions in the heart in physiological conditions and explain how its dysregulation can lead to disease development. This clarification is essential in the road for an effective personalized management of HF, particularly HFpEF, towards the development of sex-specific therapeutic approaches.

Indexed as

Sex CharacteristicsVentricular RemodelingAndrogensAnimalsEstrogensGonadal Steroid HormonesHeart FailureHumansMyocardiumAndrogensEstrogensGonadal Steroid HormonesEstrogenHeartSexSignaling pathwaysTestosterone

Identifiers

PMID34811581
OpenAlexW3216322865

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.